BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17295370)

  • 1. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
    Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
    ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
    Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
    J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
    Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
    J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
    Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
    Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM; Liu JC
    J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
    Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
    J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
    Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
    J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation.
    Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Mosti L; Menozzi G; Carraro F; Naldini A; Bernini C; Manetti F; Botta M
    Bioorg Med Chem Lett; 2004 May; 14(10):2511-7. PubMed ID: 15109642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.
    Manley PW; Breitenstein W; Brüggen J; Cowan-Jacob SW; Furet P; Mestan J; Meyer T
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5793-7. PubMed ID: 15501042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
    El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
    Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
    Indovina P; Giorgi F; Rizzo V; Khadang B; Schenone S; Di Marzo D; Forte IM; Tomei V; Mattioli E; D'Urso V; Grilli B; Botta M; Giordano A; Pentimalli F
    Oncogene; 2012 Feb; 31(7):929-38. PubMed ID: 21785466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.